Wedelolactone inhibits adipogenesis through the ERK pathway in human adipose tissue-derived mesenchymal stem cells

• Published in: Journal of cellular biochemistry 2012-11, Vol.113 (11), p.3436-3445
• Main Authors: Lim, Seyoung, Jang, Hyun-Jun, Park, Eun Hee, Kim, Jung Kuk, Kim, Jung-Min, Kim, Eung-Kyun, Yea, Kyungmoo, Kim, Yun-Hee, Lee-Kwon, Whaseon, Ryu, Sung Ho, Suh, Pann-Ghill
• Format: Article
• Language: English
• Subjects: Adipocytes - cytology; Adipocytes - drug effects; Adipocytes - metabolism; ADIPOGENESIS; Adipogenesis - drug effects; Adult; Anti-Obesity Agents - pharmacology; CCAAT-Enhancer-Binding Protein-alpha - antagonists & inhibitors; CCAAT-Enhancer-Binding Protein-alpha - genetics; Cell Differentiation; Coumarins - pharmacology; Fatty Acid-Binding Proteins - antagonists & inhibitors; Fatty Acid-Binding Proteins - genetics; Female; Flavonoids - pharmacology; Gene Expression Regulation - drug effects; Humans; Lipoprotein Lipase - antagonists & inhibitors; Lipoprotein Lipase - genetics; MAP Kinase Signaling System - drug effects; MESENCHYMAL STEM CELLS; Mesenchymal Stromal Cells - cytology; Mesenchymal Stromal Cells - drug effects; Mesenchymal Stromal Cells - metabolism; Middle Aged; Mitogen-Activated Protein Kinase 1 - antagonists & inhibitors; Mitogen-Activated Protein Kinase 1 - genetics; Mitogen-Activated Protein Kinase 1 - metabolism; Mitogen-Activated Protein Kinase 3 - antagonists & inhibitors; Mitogen-Activated Protein Kinase 3 - genetics; Mitogen-Activated Protein Kinase 3 - metabolism; PPAR gamma - antagonists & inhibitors; PPAR gamma - genetics; Primary Cell Culture; Subcutaneous Fat - cytology; Subcutaneous Fat - drug effects; Subcutaneous Fat - metabolism; WEDELOLACTONE
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.24220

Wedelolactone is an herbal medicine that is used to treat septic shock, hepatitis and venom poisoning. Although in differentiated and cancer cells, wedelolactone has been identified as anti‐inflammatory, growth inhibitory, and pro‐apoptotic, the effects of wedelolactone on stem cell differentiation remain largely unknown. Here, we report that wedelolactone inhibits the adipogenic differentiation of human adipose tissue‐derived mesenchymal stem cells (hAMSCs). Wedelolactone reduced the formation of lipid droplets and the expression of adipogenesis‐related proteins, such as CCAAT enhancer‐binding protein‐α (C/EBP‐α), peroxisome proliferator‐activated receptor‐γ (PPAR‐γ), lipoprotein lipase (LPL), and adipocyte fatty acid‐binding protein aP2 (aP2). Wedelolactone mediated this process by sustaining ERK activity. In addition, inhibition of ERK activity with PD98059 resulted in reversion of the wedelolactone‐mediated inhibition of adipogenic differentiation. Taken together, these results indicate that wedelolactone inhibits adipogenic differentiation through ERK pathway and suggest a novel inhibitory effect of wedelolactone on adipogenic differentiation in hAMSCs. J. Cell. Biochem. 113: 3436–3445, 2012. © 2012 Wiley Periodicals, Inc.